Rein Therapeutics EBITDA 2017-2024 | RNTX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Rein Therapeutics ebitda from 2017 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Rein Therapeutics ebitda from 2017 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$147B
Gilead Sciences (GILD)	$116B
Bristol Myers Squibb (BMY)	$115.8B
Vertex Pharmaceuticals (VRTX)	$110.2B
CSL (CSLLY)	$81.9B
Regeneron Pharmaceuticals (REGN)	$74.7B
GSK (GSK)	$69.3B
Argenex SE (ARGX)	$38.6B
Alnylam Pharmaceuticals (ALNY)	$34.4B
BioNTech SE (BNTX)	$27.6B
Illumina (ILMN)	$22.3B
BeiGene (ONC)	$21.7B
Biogen (BIIB)	$20.8B
Moderna (MRNA)	$14.8B
Insmed (INSM)	$14B
Incyte (INCY)	$13.9B
Genmab (GMAB)	$13.9B
Genmab (GNMSF)	$13.9B
Intra-Cellular Therapies (ITCI)	$13.5B
Bio-Techne Corp (TECH)	$12.5B
BioMarin Pharmaceutical (BMRN)	$11.8B
Sarepta Therapeutics (SRPT)	$11.1B
Vaxcyte (PCVX)	$10.8B
QIAGEN (QGEN)	$10.8B
Exact Sciences (EXAS)	$10.1B
Swedish Orphan Biovitrum (BIOVF)	$10.1B
Bio-Rad Laboratories (BIO.B)	$9.8B
Exelixis (EXEL)	$9.4B
Repligen (RGEN)	$9.3B
Roivant Sciences (ROIV)	$8.1B